Nimotuzumab and TGP for first-line recurrent / metastatic nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have nasopharyngeal cancer that has come back or spread to other parts of the body, and you haven't had treatment for this stage of the disease yet.
- Your tumor tests positive for a protein called EGFR (your doctor will check this).
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are able to take care of yourself (up and about at least half the day) and your blood counts and organ function are within a safe range as determined by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding nimotuzumab (an anti-EGFR antibody) to standard chemotherapy and radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. It may help the cancer respond better and control it more effectively after treatment.
This trial tests a combination of chemotherapy (GP), nimotuzumab, and sintilimab before standard treatment for locally advanced nasopharyngeal cancer. It aims to see if this approach can improve outcomes.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests a combination of three drugs—an anti-PD1 immunotherapy, nimotuzumab (targets EGFR), and capecitabine (chemotherapy)—for people whose nasopharyngeal cancer has returned or spread and no longer responds to platinum-based chemotherapy. The goal is to see if this combination can help when standard treatment stops working.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
Hear when a new Nasopharyngeal Carcinoma by AJCC V8 Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.